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Abstract
Background: Half of the patients with end-stage heart failure suffer from persistent atrial fibrillation (AF). Atrial kick (AK) accounts for 10—15%
of the ejection fraction. A device restoring AK should significantly improve cardiac output (CO) and possibly delay ventricular assist device (VAD)
implantation. This study has been designed to assess the mechanical effects of a motorless pump on the right chambers of the heart in an animal
model. Methods: Atripump is a dome-shaped biometal actuator electrically driven by a pacemaker-like control unit. In eight sheep, the device
was sutured onto the right atrium (RA). AF was simulated with rapid atrial pacing. RA ejection fraction (EF) was assessed with intracardiac
ultrasound (ICUS) in baseline, AF and assisted-AF status. In two animals, the pump was left in place for 4 weeks and then explanted. Histology
examination was carried out. The mean values for single measurement per animal with SD were analysed. Results: The contraction rate of the
device was 60 per min. RA EF was 41% in baseline, 7% in AF and 21% in assisted-AF conditions. CO was 7  0.5 l min1 in baseline, 6.2  0.5 l min1
in AF and 6.7  0.5 l min1 in assisted-AF status ( p < 0.01). Histology of the atrium in the chronic group showed chronic tissue inflammation and
no sign of tissue necrosis. Conclusions: The artificial muscle restores the AK and improves CO. In patients with end-stage cardiac failure and
permanent AF, if implanted on both sides, it would improve CO and possibly delay or even avoid complex surgical treatment such as VAD
implantation.
# 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Congestive heart failure (CHF) afflicts nearly 15 million
peopleworldwideandhalf of thepatientswithend-stageheart
failure suffer from persistent atrial fibrillation (AF) [1—4]. The
prevalence of AF increases with advancing functional severity
of heart failure and is present in nearly 30%ofpatientswith the
NewYorkHeartAssociation (NYHA)class III [5] and inasmanyas
50% of patients with the NYHA class IV heart failure [6].
Similarly, heart failure is prevalent in patients with AF.
Therefore, heart failure increases the risk for AF, and AF
increases the risk for heart failure. In patientswithCHF andAF,
when endovascular and/or surgical ablation techniques have
failed to restore the atrial kick (AK), the only possible
treatment of AF consists in the ventricular rhythm control and* Corresponding author. Address: Service de Chirurgie Cardiovasculaire,
Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, 1011 Lausanne,
CH, Switzerland.
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1010-7940/$ — see front matter # 2009 European Association for Cardio-Thoracic S
doi:10.1016/j.ejcts.2009.09.042anticoagulation therapy to avoid clot formation due to blood
pooling intoatria. So far, therearenomechanical tools thatare
able to restore theAK in suchpatients. AKaccounts for 10—15%
of the normal ventricle ejection fraction (EF) [7]. Any device
able to restore the AK should significantly improve the cardiac
output (CO) of a patient with CHF and possibly delay
ventricular assist device (VAD) implantation and/or heart
transplantation. A motorless, volume—displacement pump
based on artificial muscle technology could reproduce the AK
when placed onto a fibrillating atrium. This study has been
designed to assess the mechanical effects of this pump on the
right chambers in an animal model of AF.
2. Material and methods
2.1. Description of the atrial assist device
Atripump (Nanosin Sarl, Switzerland) is a dome-shaped,
silicone-coated nitinol actuator, 5  45 mm, controlled by a
urgery. Published by Elsevier B.V. All rights reserved.
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Fig. 1. The Atripump components are the dome (on the left) made of nitinol
fibres embedded in a silicone rubber and the control unit (on the right).pacemaker-like unit and powered with a lithium-ion external
battery (Fig. 1). The control unit is able to detect cardiac
activity from epicardial wires as a classic pacemaker does,
and delivers a given current to the nitinol wire, according to a
predetermined algorithm. When electrically heated, the
nitinol wire reduces its length, thus causing a shortening of
the dome concavity. Once the current is switched off, the
wire goes back to its initial length, restoring the initial
concavity of the dome. The changes in dome concavity result
in volume displacement. Similar to natural muscles, the
nitinol fibres reduce their length when electrically stimu-
lated; hence, the concept of motorless motion or artificial
muscles. This concept, the technical characteristics of the
device and the preliminary in vitro results have been
extensively described in our previous publications [8,9].
2.2. Study design
The animal study was performed in compliance with the
‘Principles of Laboratory Animal Care’, formulated by the
National Society for Medical Research and the ‘Guide for Care
and Use of Laboratory Animals’, published by the National
Institute of Health (NIH publication 85-23, revised 1985). In
adult sheep, under general anaesthesia and electrocardio-
graphic (ECG) monitoring, the right atrium (RA) was
surgically exposed through right anterior thoracotomy. The
actuator (dome) was sutured onto the external surface of the
RAwith six 4/0 interrupted sutures. A temperature probe was
inserted at the apex of the dome, between the silicone
membrane and the epicardium. A second temperature probe
was inserted into the oesophagus. A Swan Ganz catheter was
inserted into the right jugular vein to acquire data on central
venous pressure (CVP) and pulmonary artery pressure (PAP).
A 10F intracardiac ultrasound probe (ICUS, Acuson, AcuNav,
Siemens) was inserted into the left jugular vein and advanced
into the RA to acquire data on RA EF. The RA EF is an estimator
of the right atrium volume changes during the cardiac cycle.
We measured the cross-sectional area of the RA keeping the
insertion of the septal leaflet as a reference point and the
probe at the superior vena cava—RA junction. Specifically,the RA EF was calculated as follows: EF = (end-diastolic
area  end systolic area/end diastolic area)  100. The same
physician carried out all measurements. A 12G catheter was
inserted in a side branch of the carotid artery to monitor
systemic blood pressure. Pacemaker wires for epicardic
temporary stimulation were placed on the RA and connected
to an external pacemaker (Biotronic Inc., Pittsburgh, PA,
USA). The haemodynamic effect of AF was obtained using
rapid epicardic pacing (600 beats min1) without affecting
ventricular rate response. Sinus rhythm re-appeared a few
minutes after the rapid pacing was switched off.
2.3. Data acquisition
Three sets of measurements were obtained: baseline, AF-
equivalent condition and assisted-AF condition. During the
assisted-AF condition, both the rapid pacing and the
Atripump, were activated. Each set included the acquisition
of the heart rate, CVP, PAP, RA EF, and central body and
epicardium temperatures. Each set of measurements lasted
for 30 min. Four consecutive sets of measurements were
carried out.
At the end of the experience, some of the animals (acute
group) were sacrificed and histology of the RA underneath the
dome was performed using haematoxylin—eosin and three-
chromic staining. To assess whether the dome causes chronic
lesions on the heart surface, other animals (chronic group)
had the cable connecting the dome to the control unit and
power source passed under the skin up to the cervical region
where it pierced the skin. In this way, both the control unit
and the power source were outside the body. The animals
were then transferred to the farm and followed up for 4
weeks. The follow-up checklist also included monitoring of
the weight, heart rate, temperature of the surface of the
atrium underneath the dome and dome functioning. A
reduction in the daily consumption of food of greater than
50% was considered as a sign of chronic pain. The experiment
would have been terminated if it caused the animal to lose
more than 5% of its initial weight. At the end of the
experience, the chronic group underwent the same sacrifice
protocol as the acute group.
2.4. Statistical analysis
Student’s paired t-test was used to test for a difference in
scores between the three sets of measurements. Mean values
for single measurement per animal with SD were analysed.
3. Results
The experiment has been conducted in eight sheep
weighing 68 4 kg. All animals were in sinus rhythm at the
beginning of the experiment.
The dome’s contraction rate was 60—80 min1 with power
supply of 10 V, 300 mA for 100 ms. The mean temperature on
the RA’s surface was 39  1.5 8C. The mean body tempera-
ture was 38  1 8C. RA EF was 41% in baseline conditions, 7%
and 21% in AF and assisted-AF, respectively. Detailed
haemodynamic results are presented in Table 1.
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Table 1
Hemodynamic changes during baseline conditions, atrial failure induce by rapid right atrial pacing (AF) and assisted atrial failure (assisted-AF). Results are expressed
with SD differences between the adjacent values are evaluated with Student’s paired t-test.
Baseline p value AF p value Assisted-AF
Mean heart rate 68  10 0.01 90  10 ns 95  11
Mean arterial pressure (mmHg) 75  22 ns 70  13 ns 69  22
Mean pulmonary pressure (mmHg) 16  2 ns 15  2 ns 17  3
Central venous pressure (cmH2O) 12  2 ns 15  6 ns 12  5
Right ventricle output (l/min) 7  0.5 0.01 6.2  0.5 0.01 6.7  0.5
RA systolic surface (cm2) 4  0.3 0.01 6.1  0.1 0.01 5.1  0.3
RA diastolic surface (cm2) 6.8  0.3 0.01 6.5  0.1 0.01 6.4  0.2
RA ejection fraction (%) 41%  5 0.01 7%  2 0.01 21%  3
Fig. 2. Acute group. Haematoxylin—eosin stain slice (25) of the right atrium
in contact with the artificial muscle. Any relevant histological changes are
visible. Note a thin layer of fibrin deposition on epicardial side (arrow). Rare
lymphocytes are present.
Fig. 3. Chronic group. Haematoxylin—eosin slice (25) of the right atrium that
has been in contact with the artificial muscle for 4 weeks. Note a thick layer of
fibrous tissue on the epicardial side. Fibrous tissue presents a gradual matura-
tion. The deeper layer is more mature (1) with respect to the external surface
(2) where immature fibroblasts and fibrin are visible (arrow). There is not
evidence of tissue necrosis.The t-test had a significant p value (<0.001) for RA EF in
baseline versus AF and in assisted-AF versus AF conditions. We
also found statistical differences between CO in baseline
versus AF and AF versus assisted-AF. In two animals (chronic
group), the device was left in place for 4 weeks, activated in
fix mode 60 min1. No technical failure occurred. The
activation was painless as demonstrated by the normal food
intake and the behaviour of the animal. The maximal
temperature of the surface of the atrium was 41.4 8C.
In the acute group, histology examination of the atrium in
contact with the artificial muscle revealed signs of acute
inflammatory reaction mediated by lymphocytes, but no
signs of necrosis or apoptosis (Fig. 2). In the chronic group,
the histology revealed chronic tissue inflammation and no
sign of tissue necrosis or apoptosis (Fig. 3).
4. Discussion
Currently, about 20 000 patients in the United States
would benefit from heart transplantation. However, the
donor pool limits the number of transplant procedures to
2300 per year [10]. Epidemiologic studies reveal an annual
incidence of heart failure in the United States and Europe
between 0.3% and 1% [4]; and patients who are on continuous
palliative inotropes have a 6-month mortality between 60%
and 75% [2,3].
These data emphasise the urgent demand for new
therapeutic options to reduce the costs of long-term
mechanical support as a bridge to transplantation.
AF has been reported to be associated with decreased
survival. Its prognostic importance in end-stage heart failure
is controversial [11]. Ramdas and co-workers recently
reported the results involving one of the largest cohort of
patients suffering from AF (about 9000 patients over 10
years) suggesting that the effects of AF on mortality is absent
in those with moderate and severe left ventricular (LV)
dysfunction [12]. However, the haemodynamic effect of
atrial contraction is well known and even if it could
sometimes be overestimated, it cannot be denied.
According to an AHA report, the factors that markedly
decrease CO during AF are loss of synchronous atrial
mechanical activity, irregular ventricular response, rapid
heart rate and impaired coronary flow [13]. Haemodynamic
impairment due to variation in R—R intervals during AF has
been demonstrated in a canine model with complete heart
block, in which CO fell by approximately 9% during irregular
ventricular pacing [7,14].
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of embolism, with a five- to sixfold increase in the risk of
stroke in non-rheumatic patients and a 17 times increase in
the risk of stroke in rheumatic patients [5].
About half of the patients suffering from end-stage CHF
have persistent AF despite ablation treatment [15]. In such a
group of patients, any treatment that is able to restore the
pump function of the atrium should theoretically increase
the CO sufficiently to improve symptoms, prevent disease
progression and eventually avoid the implantation of VADs as
a bridge to transplant or destination therapy. In other words,
the restoration of the AK could make the difference between
being at the hospital under IV-drug therapy and waiting at
home for the right donor.
The existing treatments of AF aim to restore the sinus
rhythm or, at least to reduce the ventricular response. The
only surgical intervention that potentially cures AF, rather
than palliates, is the Maze procedure. Using thermo- or cryo-
ablation techniques, either with percutaneous access or open
surgery, it is possible to isolate the parts of the RA and left
atrium (LA) where the foci triggering the AF are located.
However, the rate of patients that maintain sinus rhythm is
low in the long-term [16]. Moreover, because cardiomyocytes
are destroyed or uncoupled after surgical and/or catheter
ablation procedures, maintenance of sinus rhythm may not
necessarily result in the complete restoration of atria
transport function. Lemola et al. reported that LA EF after
ablation of chronic AF remains significantly lower than
normal [17]. Patients continue to require anticoagulation
therapy for life and thus, are exposed to the risk of
haemorrhagic complications.
The solution we propose is the first device intended to
restore the pump function of fibrillating atria, introducing
the concept of atrial-assist device. The device has been
developed to be totally implantable in the human body with
a transcutaneous energy-transfer system to recharge the
implanted battery. Atripump links the classic pacemaker
function (stimulation) to the muscles actuation function
(contraction) using electrically activated nitinol fibres. The
idea of using a nitinol actuator to rescue the weakened
heart was first introduced by Sawyer and co-workers in 1976
[18] and, more recently, by Yambe and co-workers [19]. The
VAD they developed was able to assist heart functions in the
animal experimental set-up. However, contraction cycle,
material fatigue, heating and energy supply were the major
limitations faced. We learned a lot from their experiences
and designed a pulsatile pump that overcomes the historical
limitations of nitinol wire when used as the actuator. As
previously published, the Atripump is able to pump
approximately the volume of the normal atrium under
physiologic conditions: this corresponds to 11—22 ml per
systole [19], depending on ventricular filling pressure and
preload. The Atripump stroke volume of 8 ml corresponds,
therefore, to 75% of physiologic conditions. With a
maximum output of about half a litre per minute, it clearly
satisfies the haemodynamic needs of the normal atrium.
However, one major difference with the natural muscle is
the resistance to fatigue: human cardiac muscle might last
for a hundred years and more, while wires we use with a
kinetic distortion of 5% and a tensile strength of 0.8 Kgf can
last for a few years.The restoration of the AK should reduce the vortices and
blood stagnation in the appendix far enough to considerably
reduce thrombus formation. This concept of a mechanical
anticoagulation device is new only from the engineering and
therapeutic points of view, because, in practice, it
reproduces exactly what nature does.
In clinical practice, the haemodynamic effect of atrial
contraction is echo-assessed measuring the peak velocity and
time—velocity integral of the left ventricular diastolic filling
wave during the A-wave phase [16]. In our experimental set-
up, this technique would have been less reliable than in a
patient because the animal had the chest open, it was
ventilated with positive pressure and the activation of the
dome was not synchronised with the ventricular activity.
Therefore, we decided to calculate the EF of the atrium
directly, using the ICUS. In baseline conditions, the EF of the
right atrium was 41% and dropped down to 7% when the atrial
failure was induced with rapid pacing. During this phase, ICUS
demonstrated spontaneous echo contrast in the right
appendix signifying that blood flow velocity, at least in this
area, was low enough to induce thrombus formation. When
the artificial muscle was activated at a fixed rate of 60 min1
and despite the persistency of atrial failure induced by rapid
pacing, the spontaneous echo contrast in RA disappeared and
the EF increased to 21%, proving that the AK was partially
restored. Even if this experience has been conducted only in
eight animals, the results were highly reproducible.
The effect of the pump on the output of the right ventricle
wasminimal (+0.5 l min1), but significant. However, the fact
that also the rapid atrial pacing slightly reduced the CO could
be due to the inadequacy of the animal model we used. A
healthy sheep can compensate the lost of AK through the
increase in HR and preload. We could speculate that, in a
diseased heart, this small increase in CO would have much
more impact on the clinical status and quality of life.
The atrial assist device represents a new therapeutic
concept and it should not be considered a ‘tiny VAD’. The
major differences with existing VADs concern the invasive-
ness, the efficacy and the cost. Atripump is not in contact
with the blood stream; therefore, it does not require
anticoagulation and, theoretically, should not be associated
with neurological disorders and infections that still consti-
tute major problems with the VAD treatment modality
[20,21]. We could speculate that patients with Atripump are
less exposed to infections because Atripump is totally
implantable maintaining the integrity of the skin barrier,
which is not the case when tubes pierce the skin. The area
where the driving line passes through the skin is definitely the
most common source of infections in patients with VADs.
In our model, the device was inserted through a small
thoracotomy and this approach is definitely minimally
invasive. However, in a clinical setting, this access would
not allow the exposure of the LA. In a clinical setting, a
thoracoscopic approach would permit the minimally invasive
implantation of the device on both atria.
Costs are probably one order of magnitude smaller than
for the current VADs. However, the model’s haemodynamic
performance is significantly smaller than is the case with
current VADs.
This study has several methodological limitations.
Because the study has been conducted on the right side of
P. Tozzi et al. / European Journal of Cardio-thoracic Surgery 37 (2010) 870—874874the heart, we can only speculate that this device is effective
in increasing the CO of the left ventricle and prevents
systemic embolism of cardiac origin in AF patients. The
Atripump has been developed for the RA and its shape does
not match the complex anatomy of the LA. The presence of
the four pulmonary veins and the proximity of the oesophagus
require a softer actuator having an oval or figure-eight shape.
It should be possible with such an actuator positioned in
between pulmonary veins to reproduce the natural haemo-
dynamic effect also on the LA.
The pump has been activated in a fixed mode making the
calculation of the peak velocity and time—velocity integral of
the left ventricular diastolic filling (A wave) unreliable. This
problem has been partially overcome by calculating the EF of
the RA. The model of persistent AF we used has not been
validated yet. Rapid atrial pacing (600 min1) induces atrial
failurebut it is neitherassociatedwithatrialdilatationnorwith
the contractile remodelling of thewall typically seen in chronic
AF. Thedevice presented is a prototypeand its lifetime is short.
However, components and technology are both reliable,
providing appropriate functioning of the device for years.
Last, but not least, the model we used had normal
ventricular function and did not reproduce the CHF
conditions. We would have used the model proposed by
other authors [14], inducing CHF with microinjections in
coronary arteries. However, our veterinary authority policy
tends to avoid the induction of two diseases (AF and CHF) in
chronic animal models.
5. Conclusions
Placed on the right side, the artificial muscle restores the
AK and improves CO. In patients with end-stage cardiac
failure and permanent AF, if implanted on both sides, it would
improve CO and possibly delay or even avoid complex surgical
treatment such as VAD implantation; and it should reduce the
re-hospitalisation rate. The Atripump is a small kick for weak
hearts, a big help for patients waiting for a heart transplant.
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